Executive Chair Eric So Buys $1.21M of Cybin Stock at $12.09
HELP has more than doubled off its 52-week low of $3.76.
Summary
Executive Chair Eric So bought $1.21M of Cybin stock at $12.09 per share, adding to a wave of insider buying that now tops $3.4M in the past week.
Key Events · Ownership and Investor Activity · HELP
-
Executive Chair Buys $1.21M
Eric H. L. So purchased 100,000 shares at $12.089 per share on September 4, 2026, spending $1,208,900 in a single open-market transaction.
-
Insider Buying Tops $3.4M in a Week
Combined with Chief Growth Officer Paul Glavine's $2.2M in purchases disclosed September 9-10, total recent insider buying now exceeds $3.4M.
-
Direct Holdings Reach 4.37M Shares
Post-transaction direct ownership is 4,365,014 shares, plus 53,616 shares held indirectly through his spouse.
-
Buying Near 52-Week High
The purchase at $12.09 occurred with the stock trading near its 52-week high of $14.35, indicating conviction despite the elevated price.
Analysis · HELP · Life Sciences
A fresh insider purchase signals conviction: Executive Chair Eric H. L. So bought 100,000 shares on the open market at $12.09 per share on September 4, 2026, spending $1,208,900. This is a separate insider from Chief Growth Officer Paul Glavine, whose $2.2M in purchases were disclosed over the past two days. So's purchase brings his direct holdings to 4,365,014 shares, plus 53,616 held indirectly through his spouse. The transaction occurred with the stock trading near its 52-week high of $14.35, and the filing notes it was made voluntarily — So is not subject to Section 16 reporting requirements. The combined insider buying across the executive team now exceeds $3.4M in the past week, a strong accumulation signal ahead of the Phase 3 HLP003 data readout.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.3% of the 1324 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HELP was trading at $13.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $3.76 to $14.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.